NCT05324436View on ClinicalTrials.gov

A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)

CompletedOBSERVATIONAL
Enrollment

75

Participants

Timeline

Start Date

January 8, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Mesothelioma, Malignant
Trial Locations (1)

162-0822

Local Institution, Shinjuku-ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY